Dimethyl itaconate is effective in host-directed antimicrobial responses against mycobacterial infections through multifaceted innate immune pathways.

Author:

Kim Young Jae1,Park Eun-Jin1ORCID,Lee Sang-Hee2,Silwal Prashanta3,Kim Jin-Kyung4,Yang Jeong Seong5,Whang Jake5,Jang Ji-Chan6,Kim Jin-Man1,Jo Eun-Kyeong1ORCID

Affiliation:

1. Chungnam National University School of Medicine

2. Korea Basic Science Institute

3. University of Pittsburgh

4. Keimyung University School of Medicine

5. Korea Institute of Tuberculosis

6. Gyeongsang National University Division of Life Sciences

Abstract

Abstract Background Itaconate, a crucial immunometabolite, plays a critical role in linking immune and metabolic functions to influence host defense and inflammation. Because of its insoluble nature, several cell-permeable derivatives are being developed to provide therapeutic opportunities in infectious and inflammatory diseases. Yet, it remains largely uncharacterized whether cell-permeable derivatives have potentials in promoting host-directed therapeutics (HDT) against mycobacterial infections. Here, we report dimethyl itaconate (DMI) as the promising candidate for HDT against both Mycobacterium tuberculosis (Mtb) and nontuberculous mycobacteria by orchestrating multiple innate immune programs. Results DMI per se has low bactericidal activity against Mtb, M. bovis Bacillus Calmette–Guérin (BCG), and M. avium (Mav). However, DMI robustly activated intracellular elimination of multiple mycobacterial strains (Mtb, BCG, Mav, and even to multidrug-resistant Mtb) in macrophages and in vivo. DMI significantly suppressed the production of interleukins 6 and 10, whereas it enhanced autophagy and phagosomal maturation, during Mtb infection. DMI-mediated autophagy partly contributed to antimicrobial host defenses in macrophages. Moreover, DMI significantly downregulated the activation of signal transducer and activator of transcription 3 (STAT3) signaling during infection with Mtb, BCG, and Mav. Conclusion Together, DMI has potent anti-mycobacterial activities in macrophages and in vivo through promoting multifaceted ways for innate host defenses. DMI may bring light to new candidate for HDT against Mtb and nontuberculous mycobacteria, both of which infections are often intractable with antibiotic resistance.

Publisher

Research Square Platform LLC

Reference73 articles.

1. WHO. Global tuberculosis report 2021. WHO; 2021.

2. Isoniazid induces apoptosis of activated CD4 + T cells: implications for post-therapy tuberculosis reactivation and reinfection;Tousif S;J Biol Chem,2014

3. Global trends in resistance to antituberculosis drugs. World Health Organization-international union against tuberculosis and lung disease working group on anti-tuberculosis drug resistance surveillance;Espinal MA;N Engl J Med,2001

4. MDR tuberculosis–critical steps for prevention and control;Nathanson E;N Engl J Med,2010

5. Clinical characteristics and mortality of non-tuberculous mycobacterial infection in immunocompromised vs. immunocompetent hosts;Chai J;Front Med (Lausanne),2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3